|Articles|May 1, 2002
- Applied Clinical Trials-05-01-2002
Identifying and Documenting Adverse Events at Clinical Study Sites
Improving adverse event reporting can lead to improved safety profiles and, consequently, fewer drugs pulled from the market.
Advertisement
Articles in this issue
over 23 years ago
Letters to the Editorover 23 years ago
Parents for Orphansover 23 years ago
Fraud, Abuse, and Consentover 23 years ago
Brian Koziolover 23 years ago
A Model-Based Method for Improving Protocol QualityNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
2
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
3
Using AI and Tokenized Data to Match Patients to Protocols
4
ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
